

Andreas Teufel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1415038/publications.pdf>

Version: 2024-02-01

121
papers

5,393
citations

109321

35
h-index

88630

70
g-index

127
all docs

127
docs citations

127
times ranked

9849
citing authors

#	ARTICLE	IF	CITATIONS
1	Letter to the editor: vaccination against upper respiratory infections is a matter of survival in alcoholic liver disease. <i>Gut</i> , 2023, 72, 208-209.	12.1	1
2	Conventional ultrasound for diagnosis of hepatic steatosis is better than believed. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, 1235-1248.	0.5	12
3	Follistatin-controlled activin-HNF4 α coagulation factor axis in liver progenitor cells determines outcome of acute liver failure. <i>Hepatology</i> , 2022, 75, 322-337.	7.3	14
4	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	3.7	132
5	Severe Dysbiosis and Specific <i>Haemophilus</i> and <i>Neisseria</i> Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients. <i>Clinical Infectious Diseases</i> , 2022, 75, e1063-e1071.	5.8	18
6	RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues. <i>Molecular Oncology</i> , 2022, 16, 1091-1118.	4.6	8
7	Identification of liver-derived bone morphogenetic protein (BMP)-9 as a potential new candidate for treatment of colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 343-353.	3.6	3
8	Regional differences: clinical practice guidelines on the management of hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 161-163.	1.5	0
9	Comparative response of HCC cells to sorafenib, lenvatinib, cabozantinib and regorafenib; descriptive expression analysis. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	0
10	Tumour-suppressive BMP-9 signalling in HCC. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	0
11	Post-COVID-19 Impairment of the Senses of Smell, Taste, Hearing, and Balance. <i>Viruses</i> , 2022, 14, 849.	3.3	14
12	Current Opinion about Hepatocellular Carcinoma ≤ 10 mm. <i>Digestion</i> , 2021, 102, 335-341.	2.3	10
13	Co-Medication and Nutrition in Hepatocellular Carcinoma: Potentially Preventative Strategies in Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2021, 39, 526-533.	1.9	9
14	p53-Independent Induction of p21 Fails to Control Regeneration and Hepatocarcinogenesis in a Murine Liver Injury Model. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1387-1404.	4.5	3
15	Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. <i>Cells</i> , 2021, 10, 648.	4.1	47
16	Obeticholic Acid Inhibits Anxiety via Alleviating Gut Microbiota-Mediated Microglia Accumulation in the Brain of High-Fat High-Sugar Diet Mice. <i>Nutrients</i> , 2021, 13, 940.	4.1	16
17	Presence of gustatory and olfactory dysfunction in the time of the COVID-19 pandemic. <i>BMC Infectious Diseases</i> , 2021, 21, 612.	2.9	5
18	Semiautomated quantification of the fibrous tissue response to complex three-dimensional filamentous scaffolds using digital image analysis. <i>Journal of Biomedical Materials Research - Part A</i> , 2021, , .	4.0	2

#	ARTICLE	IF	CITATIONS
19	Spatio-Temporal Multiscale Analysis of Western Diet-Fed Mice Reveals a Translationally Relevant Sequence of Events during NAFLD Progression. <i>Cells</i> , 2021, 10, 2516.	4.1	24
20	Digital Communication Strategies in Visceral Medicine. <i>Visceral Medicine</i> , 2021, 37, 1-6.	1.3	0
21	Clinical Decision Support Systems. <i>Visceral Medicine</i> , 2021, 37, 491-498.	1.3	7
22	Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 321, G252-G261.	3.4	4
23	Durable response with lenvatinib and pembrolizumab combination therapy in a patient with pre-treated metastatic cholangiocarcinoma. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 409-410.	0.9	3
24	Digital Communication Strategies in Visceral Medicine. <i>Visceral Medicine</i> , 2021, 37, 1-3.	1.3	0
25	Hepatic Functional Pathophysiology and Morphological Damage Following Severe Burns: A Systematic Review and Meta-analysis. <i>Journal of Burn Care and Research</i> , 2021, , .	0.4	1
26	EpiCO (epirubicin, cyclophosphamide and vincristine) as treatment for extrapulmonary high-grade neuroendocrine neoplasms. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 133-136.	0.5	7
27	Self-testing for liver disease – response to an online liver test questionnaire. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 67-73.	1.5	3
28	Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1087-1088.	3.4	26
29	Benefit of adjuvant chemotherapy in high-risk colon cancer: A 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4N0M0 colon cancer. <i>European Journal of Cancer</i> , 2020, 137, 148-160.	2.8	14
30	Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 773-777.	0.5	8
31	Hepamine - A Liver Disease Microarray Database, Visualization Platform and Data-Mining Resource. <i>Scientific Reports</i> , 2020, 10, 4760.	3.3	5
32	BMP-9 Modulates the Hepatic Responses to LPS. <i>Cells</i> , 2020, 9, 617.	4.1	15
33	Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1033-1050.	2.5	14
34	Ustekinumab serum concentrations are associated with clinical outcomes in Crohn's disease – a regional multi-center pilot study. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 439-444.	0.5	11
35	TGF- β 2 silencing to target biliary-derived liver diseases. <i>Gut</i> , 2020, 69, 1677-1690.	12.1	31
36	Prognostic Significance and Functional Relevance of Olfactomedin 4 in Early-Stage Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00124.	2.5	6

#	ARTICLE	IF	CITATIONS
37	TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. <i>Cell Death and Disease</i> , 2020, 11, 212.	6.3	90
38	Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 2509-2526.	8.2	29
39	Digital Gastroenterology. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 493-496.	0.9	1
40	Autoimmune Hepatitis: a Review of Established and Evolving Treatments. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 429-443.	0.9	3
41	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. <i>Gut</i> , 2019, 68, 1099-1107.	12.1	100
42	Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 705-715.	4.4	18
43	Random gene sets in predicting survival of patients with hepatocellular carcinoma. <i>Journal of Molecular Medicine</i> , 2019, 97, 879-888.	3.9	15
44	Pharmacological treatment of hepatocellular carcinoma with cavoatrial tumor thrombus – case series and literature review. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, 501-507.	0.5	6
45	Management of immune related adverse events induced by immune checkpoint inhibition. <i>Cancer Letters</i> , 2019, 456, 80-87.	7.2	36
46	Surveillance of hepatocellular carcinoma by medical imaging. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 1904-1910.	2.0	9
47	Editorial: Systems Biology and Bioinformatics in Gastroenterology and Hepatology. <i>Frontiers in Physiology</i> , 2019, 10, 1438.	2.8	0
48	Impact of Direct Acting Antiviral (DAA) Treatment on Glucose Metabolism and Reduction of Pre-diabetes in Patients with Chronic Hepatitis C. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 27, 281-289.	0.9	27
49	Benefit of adjuvant chemotherapy in patients with high-risk UICC II colon cancer T4N0M0: A ten-year population-based analysis of 3544 cases.. <i>Journal of Clinical Oncology</i> , 2019, 37, 628-628.	1.6	0
50	Contrast enhanced ultrasound in mixed hepatocellular cholangiocarcinoma: Case series and review of the literature. <i>Digestive and Liver Disease</i> , 2018, 50, 401-407.	0.9	14
51	Hepatic Smad7 overexpression causes severe iron overload in mice. <i>Blood</i> , 2018, 131, 581-585.	1.4	10
52	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1517-1524.	12.1	42
53	Evolutionary Distance Predicts Recurrence After Liver Transplantation in Multifocal Hepatocellular Carcinoma. <i>Transplantation</i> , 2018, 102, e424-e430.	1.0	4
54	Advanced Mucinous Colorectal Cancer: Epidemiology, Prognosis and Efficacy of Chemotherapeutic Treatment. <i>Digestion</i> , 2018, 98, 143-152.	2.3	40

#	ARTICLE	IF	CITATIONS
55	Activation of silent mating type information regulation 2 homolog 1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation. <i>Hepatology</i> , 2017, 65, 2074-2089.	7.3	7
56	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 269-273.	21.4	230
57	Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice. <i>Oncotarget</i> , 2017, 8, 13059-13072.	1.8	35
58	Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival. <i>Oncotarget</i> , 2017, 8, 71002-71011.	1.8	24
59	Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues from Patients. <i>Gastroenterology</i> , 2016, 151, 513-525.e0.	1.3	180
60	Increased liver carcinogenesis and enrichment of stem cell properties in livers of Dickkopf 2 (Dkk2) deleted mice. <i>Oncotarget</i> , 2016, 7, 28903-28913.	1.8	6
61	Predictive Scores in Primary Biliary Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 438-447.	2.2	12
62	Tumor-infiltrating, interleukin-33-producing effector-memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survival. <i>Hepatology</i> , 2015, 61, 1957-1967.	7.3	84
63	Irreversible Electroporation of Malignant Hepatic Tumors - Alterations in Venous Structures at Subacute Follow-Up and Evolution at Mid-Term Follow-Up. <i>PLoS ONE</i> , 2015, 10, e0135773.	2.5	32
64	Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis. <i>PLoS ONE</i> , 2015, 10, e0140525.	2.5	8
65	Familial amyloidosis: Great progress for an orphan disease. <i>Journal of Hepatology</i> , 2015, 62, 483-485.	3.7	5
66	Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites. <i>Liver International</i> , 2015, 35, 207-214.	3.9	28
67	Causal Modeling of Cancer-Stromal Communication Identifies PAPP A as a Novel Stroma-Secreted Factor Activating NF- κ B Signaling in Hepatocellular Carcinoma. <i>PLoS Computational Biology</i> , 2015, 11, e1004293.	3.2	22
68	Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer. <i>BMC Cancer</i> , 2015, 15, 419.	2.6	18
69	Translating bioinformatics in oncology: guilt-by-profiling analysis and identification of KIF18B and CDCA3 as novel driver genes in carcinogenesis. <i>Bioinformatics</i> , 2015, 31, 216-224.	4.1	63
70	Bioinformatics and database resources in hepatology. <i>Journal of Hepatology</i> , 2015, 62, 712-719.	3.7	31
71	Association of autoimmune hepatitis and systemic lupus erythematosus: A case series and review of the literature. <i>World Journal of Gastroenterology</i> , 2014, 20, 12662.	3.3	42
72	CellMiner-HCC: a microarray-based expression database for hepatocellular carcinoma cell lines. <i>Liver International</i> , 2014, 34, 621-631.	3.9	15

#	ARTICLE	IF	CITATIONS
73	To Biopsy or Not to Biopsy: Evaluation of a Large German Cohort of Patients with Abnormal Liver Tests of Unknown Etiology. <i>Digestion</i> , 2014, 89, 310-318.	2.3	2
74	DNA Methylation Analysis in Nonalcoholic Fatty Liver Disease Suggests Distinct Disease-Specific and Remodeling Signatures after Bariatric Surgery. <i>Cell Metabolism</i> , 2013, 18, 296-302.	16.2	424
75	Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. <i>Hepatology</i> , 2013, 58, 1054-1064.	7.3	138
76	Next generation sequencing of HCC from European and Asian HCC cohorts. Back to p53 and Wnt/ β -catenin. <i>Journal of Hepatology</i> , 2013, 58, 622-624.	3.7	11
77	Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at <i>GPR35</i> and <i>TCF4</i> . <i>Hepatology</i> , 2013, 58, 1074-1083.	7.3	150
78	Next generation sequencing of the Ago2 interacting transcriptome identified chemokine family members as novel targets of neuronal microRNAs in hepatic stellate cells. <i>Journal of Hepatology</i> , 2013, 58, 335-341.	3.7	18
79	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , 2013, 45, 670-675.	21.4	339
80	Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. <i>Gut</i> , 2012, 61, 1733-1743.	12.1	159
81	Identification of <i>RARRES1</i> as a core regulator in liver fibrosis. <i>Journal of Molecular Medicine</i> , 2012, 90, 1439-1447.	3.9	10
82	Novel insights in the genetics of HCC recurrence and advances in transcriptomic data integration. <i>Journal of Hepatology</i> , 2012, 56, 279-281.	3.7	19
83	Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies. <i>Journal of Hepatology</i> , 2012, 56, 267-275.	3.7	150
84	Snapshot liver transcriptome in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 990-992.	3.7	11
85	Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. <i>Journal of Hepatology</i> , 2012, 57, 366-375.	3.7	196
86	Liver-specific overexpression of matrix metalloproteinase 9 (MMP9) in transgenic mice accelerates development of hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2012, 51, 439-448.	2.7	23
87	Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. <i>Nature Genetics</i> , 2011, 43, 17-19.	21.4	221
88	Liver specific overexpression of platelet-derived growth factor accelerates liver cancer development in chemically induced liver carcinogenesis. <i>International Journal of Cancer</i> , 2011, 128, 1259-1268.	5.1	59
89	Pregnancy in primary sclerosing cholangitis. <i>Gut</i> , 2011, 60, 1117-1121.	12.1	63
90	Microarray-Based Gene Expression Analysis of Hepatocellular Carcinoma. <i>Current Genomics</i> , 2010, 11, 261-268.	1.6	30

#	ARTICLE	IF	CITATIONS
91	Concurrent Autoimmune Diseases in Patients With Autoimmune Hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 208-213.	2.2	181
92	Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. <i>Hepatology</i> , 2010, 51, 1226-1236.	7.3	106
93	Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. <i>International Journal of Cancer</i> , 2010, 126, 2049-2066.	5.1	78
94	Mutational Characterization of the Bile Acid Receptor TGR5 in Primary Sclerosing Cholangitis. <i>PLoS ONE</i> , 2010, 5, e12403.	2.5	106
95	Collecting evidence for a stem cell hypothesis in HCC. <i>Gut</i> , 2010, 59, 870-871.	12.1	10
96	p73 is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. <i>Cell Cycle</i> , 2010, 9, 2629-2639.	2.6	25
97	Liver-specific Ldb1 deletion results in enhanced liver cancer development. <i>Journal of Hepatology</i> , 2010, 53, 1078-1084.	3.7	16
98	IFN- γ -Induced Apoptosis in Hepatocellular Carcinoma Involves Promyelocytic Leukemia Protein and TRAIL Independently of p53. <i>Cancer Research</i> , 2009, 69, 855-862.	0.9	73
99	Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. <i>Hepatology</i> , 2009, 49, 627-636.	7.3	130
100	Intraflagellar transport protein 172 is essential for primary cilia formation and plays a vital role in patterning the mammalian brain. <i>Developmental Biology</i> , 2009, 325, 24-32.	2.0	100
101	A systems biology perspective on cholangiocellular carcinoma development: Focus on MAPK-signaling and the extracellular environment. <i>Journal of Hepatology</i> , 2009, 50, 1122-1131.	3.7	18
102	Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 489-495.	2.2	146
103	Update on autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , 2009, 15, 1035.	3.3	28
104	Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2009, 15, 449.	3.3	34
105	Hepatocellular carcinoma in patients with autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , 2009, 15, 578.	3.3	64
106	The longevity assurance homologue of yeast lag1 (Lass) gene family (review). <i>International Journal of Molecular Medicine</i> , 2009, 23, 135-40.	4.0	35
107	Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. <i>Gene</i> , 2008, 423, 23-28.	2.2	52
108	Genome-wide analysis of factors regulating gene expression in liver. <i>Gene</i> , 2007, 389, 114-121.	2.2	6

#	ARTICLE	IF	CITATIONS
109	Genetics of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 2271.	3.3	116
110	Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy?. <i>World Journal of Gastroenterology</i> , 2007, 13, 3605.	3.3	32
111	Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients. <i>World Journal of Gastroenterology</i> , 2006, 12, 5513.	3.3	23
112	Characterization of human gene encoding SLA/LP autoantigen and its conserved homologs in mouse, fish, fly, and worm. <i>World Journal of Gastroenterology</i> , 2006, 12, 902.	3.3	6
113	Actin binding LIM protein 3 (abLIM3). <i>International Journal of Molecular Medicine</i> , 2006, 17, 129-33.	4.0	21
114	Current bioinformatics tools in genomic biomedical research (Review). <i>International Journal of Molecular Medicine</i> , 2006, 17, 967-73.	4.0	29
115	Characterization of OEFT, a LIM protein. <i>International Journal of Molecular Medicine</i> , 2005, 15, 513-8.	4.0	4
116	In silico characterization of LZTS3, a potential tumor suppressor. <i>Oncology Reports</i> , 2005, 14, 547-51.	2.6	12
117	In silico characterization of an Iroquois family-related homeodomain protein. <i>International Journal of Molecular Medicine</i> , 2005, 16, 443-8.	4.0	1
118	LASS6, an additional member of the longevity assurance gene family. <i>International Journal of Molecular Medicine</i> , 2005, 16, 905-10.	4.0	14
119	Frcp1 and Frcp2, two novel fibronectin type III repeat containing genes. <i>Gene</i> , 2002, 297, 79-83.	2.2	122
120	Mbx, a novel mouse homeobox gene. <i>Development Genes and Evolution</i> , 2002, 212, 104-106.	0.9	11
121	Treatment of Advanced Gastric Cancer with Etoposide, Folinic Acid, and Fluorouracil in the Clinical Setting. <i>Medical Oncology</i> , 2002, 19, 43-54.	2.5	8